Bladder cancer: advances in biology and treatment

Bosl, George J.; Fair, William R.; Herr, Harry W.; Bajorin, Dean F.; Dalbagni, Guido; Sarkis, Álvaro S.; Reuter, Victor E.; Cordon‐Cardo, Carlos; Sheinfeld, Joel; Scher, Howard I.

doi:10.1016/1040-8428(94)90041-8

Cited by 6 publications

(2 citation statements)

References 149 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The patient with NSCLC received concurrent 3-AP and irinotecan, and the patient with bladder cancer received 3-AP and doxorubicin. However, given the single agent response rate of second-line irinotecan in metastatic NSCLC is less than 5% (24) and the single agent response rate for doxorubicin in bladder cancer is 17% (25), our data suggests that increased baseline expression of RRM2 and 3-AP may contribute to the activity of the regimen.…”

Section: Discussionmentioning

confidence: 81%

Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors

Kolesar

Huang

Eickhoff

et al. 2008

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

Purpose-The purpose of this study was to evaluate baseline RRM2 protein and gene expression in tumors of patients receiving 3-AP.Experimental Design-Tumor blocks from patients enrolled in phase I and II clinical studies using 3-AP, were evaluated for RRM2 gene and protein expression by quantitative real time polymerase chain reaction (Q-RTPCR) and automated quantitative analysis, (AQUA).Results-Esophageal and gastric cancers overexpressed RRM2 protein when compared to prostate cancer (Z-score, 0.68 ± 0.94 SD, vs 0.41 ± 0.84SD, respectively,; p=0.04). Esophageal and gastric cancers also overexpressed RRM2 mRNA when compared to prostate cancer (relative gene expression 2.56 ± 1.49 SD, vs 0.29 ± 0.20 SD, respectively,; p=0.02). Protein and gene expression were moderately associated (Spearman's rank correlation =0.30; p=0.12). Conclusion-RRM2gene and protein expression varies by tumor type and may predict response to 3-AP.

show abstract

Section: Discussionmentioning

confidence: 81%

Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors

Kolesar

Huang

Eickhoff

et al. 2008

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

show abstract

“…For the majority of patients presenting with superficial bladder tumors, death from metastatic disease results in approximately 20-40% of UC patients (1). Systemic chemotherapies including cisplatin, gemicitabine, or taxol are used for locally advanced disease or metastatic disease (2), but about 30-50% of advanced UC cells do not respond to these chemotherapeutic agent-based therapies (3). A common feature among chemoresistant and metastatic tumor cells is that they exhibit profound resistance to apoptosis (4).…”

Section: Introductionmentioning

confidence: 99%

Ling-Zhi Polysaccharides Potentiate Cytotoxic Effects of Anticancer Drugs against Drug-Resistant Urothelial Carcinoma Cells

Huang

Chen

Wu³

et al. 2010

J. Agric. Food Chem.

View full text Add to dashboard Cite

The combined effects of ling-zhi polysaccharide fraction 3 (LZP-F3) and anticancer drugs (cisplatin and arsenic trioxide) were examined in three human urothelial carcinoma (UC) cells (parental, NTUB1; cisplatin-resistant, N/P(14); and arsenic-resistant, N/As(0.5)). MTT assay and median-effect analysis revealed that LZP-F3 could profoundly reverse the chemosensitivity of N/P(14) and N/As(0.5) to cisplatin and arsenic, respectively, in a dose-dependent manner, which involved activation of p38 and down-regulation of Akt and XPA. A dose of 10 mug/mL of LZP-F3 induced significant G1 arrest in N/P(14) and N/As(0.5) cells by flow cytometry, which may be mediated by the induction of p21(WAF1/CIP1). The combination of LZP-F3 and arsenic trioxide produced a significant synergistic growth inhibition of NTUB1 and N/As(0.5) cells. Similar results were also found in N/P(14) cells. These molecular events of combined effects involved significant and earlier induction of Fas, caspase 3 and 8 activation, Bax and Bad up-regulation, Bcl-2 and Bcl-x(L) down-regulatuion, and cytochrome c release.

show abstract

Therapie des muskelinvasiven und des lokal fortgeschrittenen Blasenkarzinoms im Jahr 2004

Schostak

Miller

Blasenkarzinom

View full text Add to dashboard Cite

Bladder cancer: advances in biology and treatment

Cited by 6 publications

References 149 publications

Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors

Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors

Ling-Zhi Polysaccharides Potentiate Cytotoxic Effects of Anticancer Drugs against Drug-Resistant Urothelial Carcinoma Cells

Therapie des muskelinvasiven und des lokal fortgeschrittenen Blasenkarzinoms im Jahr 2004

Contact Info

Product

Resources

About